Novel paradigm for immunotherapy of breast cancer by engaging prophylactic immunity against hepatitis B

BACKGROUND: Immunotherapy of patients suffering from the human epidermal growth factor receptor 2 overexpressing (HER-2(+)) breast cancers with the anti-HER-2 antibodies results in increase of the patients’ overall survival. However, no prophylactic vaccine is available against HER-2(+) breast cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Malecki, Marek, Sabo, Chelsea, Foorohar, Afsoon, Tombokan, Xenia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990520/
https://www.ncbi.nlm.nih.gov/pubmed/27539579
http://dx.doi.org/10.1186/s40169-016-0111-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990520/
https://www.ncbi.nlm.nih.gov/pubmed/27539579
http://dx.doi.org/10.1186/s40169-016-0111-8

Ejemplares similares